hifibio-logo
  • About
  • Pipeline
  • DIS® Platform
  • Partnering
  • News
  • Join Us

News

  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us

Latest News

Apr 29, 2025

HiFiBiO Therapeutics to Present Preclinical Data for A Novel Immunology Antibody at the 2025 Annual Meeting of the Clinical Immunology Society 

All  Filter By:

Jun 14, 2021

HiFiBiO Therapeutics Closes $75 Million Series D Financing to Accelerate Pipeline with Two Lead Immuno-Oncology Programs and Validate its DIS® Approach in the Clinic

Logo-RGB-72
Jun 11, 2021

HiFiBiO Therapeutics Announces Publication in Science Advances of its High-Throughput Functional Screening for Next-Generation Cancer Immunotherapy

Logo-RGB-72
May 11, 2021

HiFiBiO Therapeutics Announces Publication in Nature Communications on its SARS-CoV-2 Neutralizing Monoclonal Antibody

Apr 12, 2021

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

Apr 12, 2021

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

< 1 … 6 7 8 9 10 … 17 >

oncoverity logo

© 2025 HiFiBiO Therapeutics, Inc.
All Rights Reserved.

Contact

contact@hifibio.com 237 Putnam Ave
Cambridge, MA 02139

Follow Us

Legal

Privacy Policy
Disclaimer
logo
  • About
    • Company Overview
    • Leadership
    • Scientific Advisory Board
    • Board of Directors
    • Scientific Founders
    • Contact
  • Pipeline
    • Overview
    • Programs
      • EMUNKITUG (HFB200301)
      • HFB200603
      • NUVUSTOTUG (HFB301001)
      • HFB200604
      • HFB3024
  • DIS® Platform
  • Partnering
    • Partnerships
    • Open-Innovation Hub
  • News
  • Join Us